Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Leases (2022 - 2025)

Historic Current Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • Entrada Therapeutics' Current Leases fell 4378.39% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 4378.39%. This contributed to the annual value of $7.6 million for FY2024, which is 442.53% down from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Current Leases is $4.4 million, which was down 4378.39% from $5.5 million recorded in Q2 2025.
  • Entrada Therapeutics' Current Leases' 5-year high stood at $8.6 million during Q2 2024, with a 5-year trough of $4.4 million in Q3 2025.
  • Moreover, its 4-year median value for Current Leases was $7.7 million (2024), whereas its average is $7.4 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Current Leases surged by 1686.61% in 2024, and later plummeted by 4378.39% in 2025.
  • Entrada Therapeutics' Current Leases (Quarter) stood at $8.4 million in 2022, then dropped by 5.91% to $7.9 million in 2023, then dropped by 4.43% to $7.6 million in 2024, then tumbled by 42.45% to $4.4 million in 2025.
  • Its Current Leases stands at $4.4 million for Q3 2025, versus $5.5 million for Q2 2025 and $6.5 million for Q1 2025.